WebmedCentral Editor
View all WebmedCentral Editors
No Image

Dr. David Wareham

Senior Clinical Lecturer
Queen Mary University, London
4 Newark Street

Brief Biography:

David Wareham qualified (MB BS) from the London Hospital Medical College in 1994 and trained in general medicine in East London and Essex before specialist training in Medical Microbiology in North East Thames (FRCPath). He was awarded a Clinical Training Fellowship to study aspects of Pseudomonas aeruginosa pathogenicity at Queen Mary University in 2002 and was appointed as Senior Clinical Lecturer in Microbiology in July 2005 (PhD). He is an Honorary Consultant Microbiologist at Barts and The London, Newham University and Homerton NHS Trusts where he is responsible for aspects of intensive care microbiology. His current research interests include the molecular epidemiology, mechanisms of resistance and pathogenicity of Gram-negative nosocomial pathogens.


Academic positions:

July 2005 – present

Clinical   Senior Lecturer and Honorary Consultant in Medical Microbiology

QueenMary UniversityLondon  and Barts and TheLondon  NHS Trust

10 HEFCE funded programmed activities; 5   academic, 5 clinical

Clinical lead for critical care and cystic   fibrosis microbiology

January 2006 – present

Honorary   Consultant in Microbiology

HomertonUniversity  HospitalNHS Foundation Trust


Research interests:

Antimicrobial resistance represents a formidable challenge to modern healthcare, with the real prospect that common infections may soon become untreatable. Our group is involved in characterizing the mechanisms underlying the development and persistence of resistance as well as the consequences this may have on the organism and its capacity to cause human disease. We combine genomics, molecular biology, in-vitro and in-vivo (invertebrates), epidemiological and clinical data in an attempt to dissect the complex relationship between host, pathogen and resistance. Our research is driven by the problems we encounter in daily clinical practice and in recent years has focused on multi-drug resistant Gram-negative bacteria such as Acinetobacter baumannii, Stenotrophomonas maltophilia and carbapenem-resistant Enterobacteria.   Areas of particular interest include the identification of novel resistance determinants, evaluation of novel therapeutic strategies, virulence studies of emerging pathogens and interventions to prevent the spread of resistant organisms in the nosocomial environment.  Our work has been funded by industry, charities and research councils and we are keen to hear from prospective students, scientists and other healthcare professionals who would like to join our group and with whom we can collaborate


What I think of the idea behind WebmedCentral:

Shoudl be usefull in fostering collaborations